Barclays PLC Supernus Pharmaceuticals, Inc. Call Options Transaction History

Barclays PLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2019 Feb 10, 2020	BUY	$19.93 - $29.13 $1.31 Million - $1.92 Million	65,800 Added 69.48%	160,500 $3.81 Million
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $2.31 Million - $3.02 Million	90,600 Added 2209.76%	94,700 $2.6 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $149,940 - $203,490	3,400 Added 485.71%	4,100 $245,000
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $25,725 - $34,755	700	700 $28,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.